JOSEPH David DIAZ
- Type
- Physician · Allopathic & Osteopathic Physicians / Allergy & Immunology
- Where
- Maryville, IL
- NPI
- 1417948241
- Received
- $1,131,990 in 2,145 records, 2019 to 2025; ownership interests with $95,000 invested
- As principal investigator
- $651,310 of research payments to others in 124 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 221 | $185,755 |
| 2024 | General payment | 296 | $174,294 |
| 2023 | General payment | 402 | $211,688 |
| 2022 | General payment | 408 | $225,996 |
| 2021 | General payment | 329 | $152,570 |
| 2021 | Ownership or investment interest | 3 | $95,000 |
| 2020 | General payment | 160 | $30,572 |
| 2019 | General payment | 326 | $151,112 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 331 | $842,646 |
| Travel and Lodging | 444 | $131,699 |
| Consulting Fee | 41 | $101,696 |
| Ownership or investment interest | 3 | $95,000 |
| Food and Beverage | 1,303 | $48,310 |
| Honoraria | 2 | $5,747 |
| Compensation for serving as faculty or as a speaker for a medical education program | 1 | $1,000 |
| Education | 19 | $865 |
| Debt forgiveness | 1 | $23 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | GENZYME CORPORATION | $28 | Food and Beverage | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-12-17 | AstraZeneca Pharmaceuticals LP | $3,255 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-12-17 | CSL Behring | $25 | Food and Beverage | In-kind items and services | Andembry Biological, Hematology | 2025 | |
| 2025-12-16 | Genentech USA, Inc. | $29 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-12-11 | Genentech USA, Inc. | $14 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-12-09 | AstraZeneca Pharmaceuticals LP | $422 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-12-09 | AstraZeneca Pharmaceuticals LP | $112 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-12-09 | AstraZeneca Pharmaceuticals LP | $74 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-12-09 | AstraZeneca Pharmaceuticals LP | $51 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-12-09 | AstraZeneca Pharmaceuticals LP | $26 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-11-24 | AstraZeneca Pharmaceuticals LP | $450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-11-09 | Genentech USA, Inc. | $148 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-11-06 | Amgen Inc. | $10 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-11-03 | AstraZeneca Pharmaceuticals LP | $61 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-24 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-23 | CSL Behring | $6,479 | Consulting Fee | Cash or cash equivalent | Andembry Biological, Hematology | 2025 | |
| 2025-10-23 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage (3 payments) | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-22 | Azurity Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | ALVESCO Drug, ANTI-INFLAMMATORY | 2025 | |
| 2025-10-14 | Genentech USA, Inc. | $23 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-10-13 | Genentech USA, Inc. | $14 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-10-04 | CSL Behring | $85 | Food and Beverage | In-kind items and services | Andembry Biological, Hematology | 2025 | |
| 2025-10-04 | CSL Behring | $67 | Food and Beverage | In-kind items and services | Andembry Biological, Hematology | 2025 | |
| 2025-10-04 | CSL Behring | $47 | Food and Beverage | In-kind items and services | Andembry Biological, Hematology | 2025 | |
| 2025-10-03 | CSL Behring | $184 | Travel and Lodging | In-kind items and services | Andembry Biological, Hematology | 2025 | |
| 2025-09-30 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-26 | Novartis Pharmaceuticals Corporation | $477 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-26 | Novartis Pharmaceuticals Corporation | $219 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-26 | Novartis Pharmaceuticals Corporation | $198 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-26 | Novartis Pharmaceuticals Corporation | $10 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-25 | Novartis Pharmaceuticals Corporation | $139 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-23 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-23 | AstraZeneca Pharmaceuticals LP | $125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-09-23 | Regeneron Healthcare Solutions, Inc. | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-22 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-22 | Genentech USA, Inc. | $130 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-09-17 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-17 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-09-16 | AstraZeneca Pharmaceuticals LP | $39 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-11 | AstraZeneca Pharmaceuticals LP | $442 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-11 | AstraZeneca Pharmaceuticals LP | $335 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-11 | AstraZeneca Pharmaceuticals LP | $134 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-10 | AstraZeneca Pharmaceuticals LP | $116 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-08-21 | GENZYME CORPORATION | $28 | Food and Beverage | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-08-20 | GlaxoSmithKline, LLC. | $20 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-08-12 | AstraZeneca Pharmaceuticals LP | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-08-07 | AstraZeneca Pharmaceuticals LP | $123 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-08-05 | AstraZeneca Pharmaceuticals LP | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-08-04 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-08-04 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-08-04 | AstraZeneca Pharmaceuticals LP | $70 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-31 | AstraZeneca Pharmaceuticals LP | $193 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-07-31 | AstraZeneca Pharmaceuticals LP | $125 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-07-29 | AstraZeneca Pharmaceuticals LP | $279 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-07-29 | AstraZeneca Pharmaceuticals LP | $205 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-07-29 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-07-24 | AstraZeneca Pharmaceuticals LP | $62 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-21 | CSL Behring | $19 | Food and Beverage | In-kind items and services | Andembry Biological, Hematology | 2025 | |
| 2025-07-17 | Genentech USA, Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Xolair Biological, Immunology | 2025 | |
| 2025-07-15 | AstraZeneca Pharmaceuticals LP | $120 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-10 | AstraZeneca Pharmaceuticals LP | $697 | Consulting Fee | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-17 | Novartis Pharmaceuticals Corporation | $137 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-16 | AstraZeneca Pharmaceuticals LP | $950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-11 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-06-11 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-06-10 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-06-08 | Novartis Pharmaceuticals Corporation | $98 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-08 | Novartis Pharmaceuticals Corporation | $98 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-06 | AstraZeneca Pharmaceuticals LP | $126 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-05 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-04 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-06-03 | AstraZeneca Pharmaceuticals LP | $358 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-03 | AstraZeneca Pharmaceuticals LP | $347 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-03 | AstraZeneca Pharmaceuticals LP | $87 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-05-29 | Genentech USA, Inc. | $27 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-05-28 | Takeda Pharmaceuticals U.S.A., Inc. | $15 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-05-28 | Genentech USA, Inc. | $3 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-05-23 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-22 | AstraZeneca Pharmaceuticals LP | $30 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-21 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-21 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-20 | AstraZeneca Pharmaceuticals LP | $462 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-20 | AstraZeneca Pharmaceuticals LP | $143 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-20 | AstraZeneca Pharmaceuticals LP | $119 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-20 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-19 | AstraZeneca Pharmaceuticals LP | $26 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-14 | CSL Behring | $25 | Food and Beverage | In-kind items and services | Haegarda Biological, Immunology | 2025 | |
| 2025-05-07 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-05-07 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-05-07 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-06 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FASENRA Biological, Respiratory | 2025 | |
| 2025-04-29 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-29 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-29 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-29 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-29 | AstraZeneca Pharmaceuticals LP | $327 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-29 | AstraZeneca Pharmaceuticals LP | $127 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-29 | AstraZeneca Pharmaceuticals LP | $125 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-29 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-26 | Genentech USA, Inc. | $338 | Travel and Lodging | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-04-26 | Genentech USA, Inc. | $78 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-04-26 | Takeda Pharmaceuticals U.S.A., Inc. | $37 | Food and Beverage | In-kind items and services | TAKHZYRO Biological, GENETIC DISEASE | 2025 | |
| 2025-04-26 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-25 | AstraZeneca Pharmaceuticals LP | $338 | Travel and Lodging | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-04-25 | BioCryst US Sales Co., LLC | $61 | Food and Beverage | In-kind items and services | ORLADEYO Drug, Immunology | 2025 | |
| 2025-04-24 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-24 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-23 | AstraZeneca Pharmaceuticals LP | $332 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-23 | AstraZeneca Pharmaceuticals LP | $38 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-21 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-18 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-14 | AstraZeneca Pharmaceuticals LP | $465 | Consulting Fee | Cash or cash equivalent | FASENRA Biological, Respiratory | 2025 | |
| 2025-04-11 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-11 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-10 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FASENRA Biological, Respiratory | 2025 | |
| 2025-04-10 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FASENRA Biological, Respiratory | 2025 | |
| 2025-04-09 | AstraZeneca Pharmaceuticals LP | $326 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-09 | AstraZeneca Pharmaceuticals LP | $117 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-09 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-08 | AstraZeneca Pharmaceuticals LP | $460 | Travel and Lodging | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-04-08 | AstraZeneca Pharmaceuticals LP | $218 | Travel and Lodging | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-04-08 | AstraZeneca Pharmaceuticals LP | $99 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-04-08 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-04-07 | AstraZeneca Pharmaceuticals LP | $3,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-07 | Genentech USA, Inc. | $25 | Travel and Lodging | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-04-02 | AstraZeneca Pharmaceuticals LP | $804 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-02 | AstraZeneca Pharmaceuticals LP | $297 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-02 | AstraZeneca Pharmaceuticals LP | $172 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-02 | AstraZeneca Pharmaceuticals LP | $126 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-02 | AstraZeneca Pharmaceuticals LP | $122 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-02 | AstraZeneca Pharmaceuticals LP | $110 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-01 | AstraZeneca Pharmaceuticals LP | $100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FASENRA Biological, Respiratory | 2025 | |
| 2025-04-01 | AstraZeneca Pharmaceuticals LP | $41 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-01 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage (3 payments) | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-03-31 | AstraZeneca Pharmaceuticals LP | $3,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-31 | AstraZeneca Pharmaceuticals LP | $69 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-28 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-28 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-27 | ARS Pharmaceuticals Operations, Inc. | $112 | Food and Beverage | In-kind items and services | NEFFY Drug, ALLERGY | 2025 | |
| 2025-03-26 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-25 | AstraZeneca Pharmaceuticals LP | $854 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-25 | AstraZeneca Pharmaceuticals LP | $652 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-25 | AstraZeneca Pharmaceuticals LP | $286 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-25 | AstraZeneca Pharmaceuticals LP | $132 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-25 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-20 | Genentech USA, Inc. | $3,130 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Xolair Biological, Immunology | 2025 | |
| 2025-03-14 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-14 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-13 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-11 | AstraZeneca Pharmaceuticals LP | $1,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-03-11 | AstraZeneca Pharmaceuticals LP | $900 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-11 | AstraZeneca Pharmaceuticals LP | $185 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-11 | AstraZeneca Pharmaceuticals LP | $166 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-11 | AstraZeneca Pharmaceuticals LP | $122 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-11 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-10 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-05 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-03-05 | AstraZeneca Pharmaceuticals LP | $688 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-05 | AstraZeneca Pharmaceuticals LP | $194 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-05 | AstraZeneca Pharmaceuticals LP | $111 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-05 | AstraZeneca Pharmaceuticals LP | $83 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-03 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-03-01 | Amgen Inc. | $131 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-03-01 | AstraZeneca Pharmaceuticals LP | $90 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-03-01 | AstraZeneca Pharmaceuticals LP | $51 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-28 | Genentech USA, Inc. | $59 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-02-27 | AstraZeneca Pharmaceuticals LP | $842 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-27 | AstraZeneca Pharmaceuticals LP | $402 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-27 | AstraZeneca Pharmaceuticals LP | $155 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-27 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-25 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-25 | AstraZeneca Pharmaceuticals LP | $421 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-25 | AstraZeneca Pharmaceuticals LP | $177 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-25 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-21 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-21 | AstraZeneca Pharmaceuticals LP | $3,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-20 | Genentech USA, Inc. | $117 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-02-19 | AstraZeneca Pharmaceuticals LP | $349 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-19 | AstraZeneca Pharmaceuticals LP | $272 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-19 | AstraZeneca Pharmaceuticals LP | $116 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-18 | AstraZeneca Pharmaceuticals LP | $450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-18 | AstraZeneca Pharmaceuticals LP | $231 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-18 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-18 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-18 | AstraZeneca Pharmaceuticals LP | $15 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-17 | AstraZeneca Pharmaceuticals LP | $206 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-17 | AstraZeneca Pharmaceuticals LP | $179 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-17 | AstraZeneca Pharmaceuticals LP | $102 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-17 | AstraZeneca Pharmaceuticals LP | $58 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-13 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-13 | BioCryst Pharmaceuticals, Inc. | $63 | Food and Beverage | In-kind items and services | ORLADEYO Drug, Immunology | 2025 | |
| 2025-02-06 | AstraZeneca Pharmaceuticals LP | $361 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-06 | AstraZeneca Pharmaceuticals LP | $136 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-06 | AstraZeneca Pharmaceuticals LP | $119 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-05 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-04 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-04 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-03 | AstraZeneca Pharmaceuticals LP | $3,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-01-31 | AstraZeneca Pharmaceuticals LP | $3,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-01-30 | AstraZeneca Pharmaceuticals LP | $126 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-01-30 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 |
The latest 200 records of 2,145.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2023-01-01 | Novartis Pharmaceuticals Corporation | ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES OF SOUTH TEXAS | $300 | A multi center randomized double blind active and placebo controlled study to investigate the efficacy and safety of lig | 2023 |
| 2022-06-02 | Genentech, Inc. | ALLERGY & ASTHMA RESEARCH CENTER | $1,980 | THE REALITY PROJECT | 2022 |
| 2022-01-06 | Novartis Pharmaceuticals Corporation | ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES OF SOUTH TEXAS | $790 | A MULTI CENTER RANDOMIZED DOUBLE BLIND ACTIVE AND PLACEBO CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LIG | 2022 |
| 2021-01-06 | Novartis Pharmaceuticals Corporation | ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES OF SOUTH TEXAS | $816 | A MULTI CENTER RANDOMIZED DOUBLE BLIND ACTIVE AND PLACEBO CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LIG | 2021 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | ALLERGY AND ASTHMA RESEARCH CENTER | $2,077 | A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | ALLERGY AND ASTHMA RESEARCH CENTER | $5,811 | A Multicenter, Randomized, Open-label, Parallel group, Functionality, and Performance Study of an Accessorized Pre-fille | 2020 |
| 2020-12-22 | Genentech, Inc. | ALLERGY AND ASTHMA RESEARCH CENTER PA | $17,820 | THE REALITY PROJECT | 2020 |
| 2020-06-18 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $1,321 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2020 |
| 2020-05-26 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $30 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2020 |
| 2020-05-19 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $700 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2020 |
| 2020-05-11 | SANOFI US SERVICES INC. | ALLERGY AND ASTHMA RESEARCH CENTER | $2,420 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2020 |
| 2020-05-04 | SANOFI US SERVICES INC. | ALLERGY AND ASTHMA RESEARCH CENTER | $3,130 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2020 |
| 2020-04-27 | SANOFI US SERVICES INC. | ALLERGY AND ASTHMA RESEARCH CENTER | $500 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2020 |
| 2020-04-14 | Genentech, Inc. | ALLERGY AND ASTHMA RESEARCH CENTER PA | $2,982 | PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA | 2020 |
| 2020-04-13 | SANOFI US SERVICES INC. | ALLERGY AND ASTHMA RESEARCH CENTER | $4,400 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2020 |
| 2020-04-06 | SANOFI US SERVICES INC. | ALLERGY AND ASTHMA RESEARCH CENTER | $50 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2020 |
| 2020-04-01 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $600 | Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe A | 2020 |
| 2020-04-01 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $600 | Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe A | 2020 |
| 2020-04-01 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $600 | Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe A | 2020 |
| 2020-03-16 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $148 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2020 |
| 2020-03-16 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $360 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2020 |
| 2020-03-12 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $30 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2020 |
| 2020-03-03 | SANOFI US SERVICES INC. | ALLERGY AND ASTHMA RESEARCH CENTER | $550 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2020 |
| 2020-03-03 | SANOFI US SERVICES INC. | ALLERGY AND ASTHMA RESEARCH CENTER | $1,375 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2020 |
| 2020-03-03 | SANOFI US SERVICES INC. | ALLERGY AND ASTHMA RESEARCH CENTER | $3,000 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2020 |
| 2020-03-03 | SANOFI US SERVICES INC. | ALLERGY AND ASTHMA RESEARCH CENTER | $1,620 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2020 |
| 2020-03-03 | SANOFI US SERVICES INC. | ALLERGY AND ASTHMA RESEARCH CENTER | $8,173 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2020 |
| 2020-03-03 | SANOFI US SERVICES INC. | ALLERGY AND ASTHMA RESEARCH CENTER | $1,925 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2020 |
| 2020-03-03 | SANOFI US SERVICES INC. | ALLERGY AND ASTHMA RESEARCH CENTER | $1,300 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2020 |
| 2020-03-03 | SANOFI US SERVICES INC. | ALLERGY AND ASTHMA RESEARCH CENTER | $4,400 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2020 |
| 2020-03-02 | BioCryst Pharmaceuticals, Inc. | Allergy & Asthma Research Ctr, PA | $200 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two | 2020 |
| 2020-03-02 | BioCryst Pharmaceuticals, Inc. | Allergy & Asthma Research Ctr, PA | $378 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two | 2020 |
| 2020-03-02 | BioCryst Pharmaceuticals, Inc. | Allergy & Asthma Research Ctr, PA | $80 | An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Ang | 2020 |
| 2020-03-02 | BioCryst Pharmaceuticals, Inc. | Allergy & Asthma Research Ctr, PA | $125 | An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Ang | 2020 |
| 2020-03-02 | BioCryst Pharmaceuticals, Inc. | Allergy & Asthma Research Ctr, PA | $150 | An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Ang | 2020 |
| 2020-03-02 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $200 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2020 |
| 2020-02-28 | BioCryst Pharmaceuticals, Inc. | Allergy & Asthma Research Ctr, PA | $1,200 | An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Ang | 2020 |
| 2020-02-28 | BioCryst Pharmaceuticals, Inc. | Allergy & Asthma Research Ctr, PA | $16,152 | An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Ang | 2020 |
| 2020-02-25 | AstraZeneca Pharmaceuticals LP | ALLERGY AND ASTHMA RESEARCH CENTER | $9,537 | A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of | 2020 |
| 2020-02-19 | BioCryst Pharmaceuticals, Inc. | Allergy & Asthma Research Ctr, PA | $1,320 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two | 2020 |
| 2020-02-18 | SANOFI US SERVICES INC. | ALLERGY AND ASTHMA RESEARCH CENTER | $17,216 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2020 |
| 2020-02-17 | BioCryst Pharmaceuticals, Inc. | Allergy & Asthma Research Ctr, PA | $121 | An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Ang | 2020 |
| 2020-02-11 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $2,180 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2020 |
| 2020-02-11 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $100 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2020 |
| 2020-02-11 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $662 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2020 |
| 2020-02-11 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $50 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2020 |
| 2020-02-11 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $662 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2020 |
| 2020-02-04 | SANOFI US SERVICES INC. | ALLERGY AND ASTHMA RESEARCH CENTER | $4,289 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2020 |
| 2020-01-23 | AstraZeneca Pharmaceuticals LP | ALLERGY AND ASTHMA RESEARCH CENTER | $43,032 | A Multicenter, Randomized, Open-label, Parallel group, Functionality, and Performance Study of an Accessorized Pre-fille | 2020 |
| 2020-01-14 | AstraZeneca AB | ALLERGY AND ASTHMA RESEARCH CENTER | $7,140 | A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. | 2020 |
| 2020-01-02 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $1,073 | Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe A | 2020 |
| 2020-01-02 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $1,114 | Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe A | 2020 |
| 2020-01-01 | Novartis Pharmaceuticals Corporation | ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES OF SOUTH TEXAS | $13,123 | A MULTI CENTER RANDOMIZED DOUBLE BLIND ACTIVE AND PLACEBO CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LIG | 2020 |
| 2020-01-01 | Novartis Pharmaceuticals Corporation | ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES OF SOUTH TEXAS | $2,876 | A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN | 2020 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | ALLERGY AND ASTHMA RESEARCH CENTER | $15,818 | A Multicenter, Randomized, Open-label, Parallel group, Functionality, and Performance Study of an Accessorized Pre-fille | 2019 |
| 2019-12-31 | BioCryst Pharmaceuticals, Inc. | Allergy & Asthma Research Center, P.A. | $1,320 | BCX7353-204 (HAE) | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | ALLERGY AND ASTHMA RESEARCH CENTER | $5,530 | A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of | 2019 |
| 2019-12-30 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $414 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2019 |
| 2019-12-05 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $662 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2019 |
| 2019-12-02 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $700 | PH3 RANDOMIZED MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF OMALIZUMAB FOR NASAL POLYPS | 2019 |
| 2019-11-18 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $4,631 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2019 |
| 2019-11-14 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $325 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2019 |
| 2019-11-14 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $646 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2019 |
| 2019-11-14 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $1,324 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2019 |
| 2019-11-04 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $2,570 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2019 |
| 2019-11-04 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $3,000 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2019 |
| 2019-11-01 | Genentech, Inc. | ALLERGY AND ASTHMA RESEARCH CENTER PA | $10,626 | PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA | 2019 |
| 2019-10-31 | BioCryst Pharmaceuticals, Inc. | Allergy & Asthma Research Center, P.A. | $3,500 | BCX7353-204 (HAE) | 2019 |
| 2019-10-31 | BioCryst Pharmaceuticals, Inc. | Allergy & Asthma Research Center, P.A. | $1,500 | BCX7353-204 (HAE) | 2019 |
| 2019-10-22 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $5,742 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2019 |
| 2019-10-21 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $1,540 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2019 |
| 2019-10-21 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $4,930 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2019 |
| 2019-10-15 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $2,175 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2019 |
| 2019-10-10 | AstraZeneca Pharmaceuticals LP | ALLERGY AND ASTHMA RESEARCH CENTER | $117,127 | A Multicenter, Randomized, Open-label, Parallel group, Functionality, and Performance Study of an Accessorized Pre-fille | 2019 |
| 2019-10-08 | Genentech, Inc. | ALLERGY AND ASTHMA RESEARCH CENTER PA | $150 | PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA | 2019 |
| 2019-10-08 | Genentech, Inc. | ALLERGY AND ASTHMA RESEARCH CENTER PA | $3,056 | PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA | 2019 |
| 2019-09-18 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $2,923 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2019 |
| 2019-09-18 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $4,458 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2019 |
| 2019-09-05 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $1,986 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2019 |
| 2019-09-02 | Genentech, Inc. | ALLERGY AND ASTHMA RESEARCH CENTER PA | $5,094 | PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA | 2019 |
| 2019-08-21 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $5,522 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2019 |
| 2019-08-19 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $2,508 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2019 |
| 2019-07-25 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $1,254 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2019 |
| 2019-07-22 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $15,944 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2019 |
| 2019-07-02 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $4,125 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2019 |
| 2019-07-02 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $175 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2019 |
| 2019-07-02 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $1,150 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2019 |
| 2019-06-25 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $200 | PH3 RANDOMIZED MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF OMALIZUMAB FOR NASAL POLYPS | 2019 |
| 2019-06-25 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $600 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2019 |
| 2019-06-17 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $7,145 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2019 |
| 2019-06-17 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $21,896 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in | 2019 |
| 2019-06-06 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $40 | PH3 RANDOMIZED MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF OMALIZUMAB FOR NASAL POLYPS | 2019 |
| 2019-06-06 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $2,737 | PH3 RANDOMIZED MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF OMALIZUMAB FOR NASAL POLYPS | 2019 |
| 2019-06-06 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $1,400 | PH3 RANDOMIZED MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF OMALIZUMAB FOR NASAL POLYPS | 2019 |
| 2019-06-06 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $56 | PH3 RANDOMIZED MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF OMALIZUMAB FOR NASAL POLYPS | 2019 |
| 2019-06-03 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $1,324 | OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2019 |
| 2019-05-28 | Genentech, Inc. | ALLERGY AND ASTHMA RESEARCH CENTER PA | $1,927 | PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA | 2019 |
| 2019-05-23 | Genentech, Inc. | ALLERGY AND ASTHMA RESEARCH CENTER PA | $2,752 | PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA | 2019 |
| 2019-05-20 | SANOFI US SERVICES INC. | Allergy And Asthma Research Center,PA | $4,569 | One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Part | 2019 |
| 2019-05-14 | Roche Products Limited | ALLERGY AND ASTHMA RESEARCH CENTER PA | $140 | PH3 RANDOMIZED MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF OMALIZUMAB FOR NASAL POLYPS | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Maryville, IL, county Madison County, IL, state Illinois; placed by its city name.
| Measure | Place (city or town) Maryville, IL | County Madison County, IL | State Illinois |
|---|---|---|---|
| Population B01003 | 8,316 | 264,238 | 12,694,798 |
| Population, 2020 census P1 | 8,221 | 265,859 | 12,812,508 |
| Median age B01002 | 51.7 | 40.2 | 39.0 |
| Under 18 B01001 | 14.3% | 21.3% | 21.8% |
| 65 and over B01001 | 26.1% | 18.5% | 17.0% |
| Households B11001 | 3,587 | 110,134 | 5,036,449 |
| Foreign born B05002 | 3.6% | 2.2% | 14.7% |
| Median household income B19013 | $100,670 | $75,793 | $83,390 |
| Median family income B19113 | $132,238 | $97,683 | $106,018 |
| Per capita income B19301 | $51,250 | $41,560 | $46,406 |
| Poverty rate B17001 | 2.7% | 11.1% | 11.8% |
| Unemployment rate B23025 | 6.2% | 4.6% | 5.8% |
| Civilian labor force B23025 | 4,637 | 134,459 | 6,652,134 |
| Mean commute (minutes) B08013 | 29.4 | 24.9 | 27.8 |
| Bachelor's degree or higher B15003 | 43.8% | 31.0% | 37.8% |
| Housing units B25001 | 3,650 | 119,168 | 5,457,452 |
| Owner-occupied B25003 | 85.6% | 74.2% | 67.1% |
| Renters B25003 | 14.4% | 25.8% | 32.9% |
| Median home value B25077 | $261,800 | $173,000 | $263,300 |
| Median gross rent B25064 | $1,145 | $1,024 | $1,274 |
| White, not Hispanic B03002 | 85.8% | 81.8% | 58.1% |
| Black B03002 | 5.4% | 7.7% | 13.3% |
| Hispanic or Latino B03002 | 2.8% | 4.3% | 18.8% |
| Asian B03002 | 2.3% | 0.8% | 5.9% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Maryville, IL.
Comments